PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.55%
Net income growth above 1.5x GNPX's 2.91%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-4.31%
Both reduce yoy D&A, with GNPX at -2.92%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-1173.94%
Negative yoy deferred tax while GNPX stands at 19.91%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-7.99%
Both cut yoy SBC, with GNPX at -3.62%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
214.02%
Well above GNPX's 190.58% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.21%
Negative yoy AP while GNPX is 55.37%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
259.96%
Growth well above GNPX's 290.91%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
1173.94%
Some yoy increase while GNPX is negative at -19.91%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
18.46%
Operating cash flow growth below 50% of GNPX's 41.59%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
36.17%
Some CapEx rise while GNPX is negative at -8.78%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.17%
We have mild expansions while GNPX is negative at -8.78%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-70.77%
Negative yoy issuance while GNPX is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.